US STOCK
NBIX Stock Analysis
US stocks · market data · technical indicators
Neurocrine Biosciences, Inc.
NBIXUS stocksQuote delayed 15 min
9/11 上午11:36 updated
$156.57
+1.43+0.92%
Open
$154.38
High
$159.94
Low
$152.04
Volume
89.51萬
NBIX price history
+0.05%Open
156.49
Latest
156.57
High
158.35
Low
150.82
Average
154.87
Advertisement
AI Composite Technical Analysis
BetaFormula: fundamentals (40%) + technical indicators (30%) + market sentiment (30%)
AI Score80
Score range 0–100; a higher score indicates a stronger buy signal
Market Status
BuyCurrent Price$156.57
Target Price$203.541
Change %+0.92%
Institutional
Net Buying
Foreign Ownership
Reducing
Market Heat
Positive
Fundamentals (US)
P/E Ratio
22.69x
ROE
22.09%
P/B Ratio
4.31x
Dividend Yield
--
Market Insight
The composite score points to a strong buy signal (80/100), with several technical and fundamental indicators in positive territory. Return on equity of 22.09% indicates solid profitability. The target price implies roughly 30.00% upside.
This analysis is for reference only and does not constitute investment advice. Investing carries risk; educational content only.
Financial snapshot
NBIX - Neurocrine Biosciences, Inc.
EPS
6.90USD
Forward EPS
11.97USD
P/E
22.69x
Forward P/E
13.08x
P/B
4.31x
ROE
22.09%
ROA
11.70%
Operating margin
22.19%
Profit margin
20.91%
Revenue growth
39.50%
Earnings growth
31.10%
Dividend yield
--
Financial statements
| 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|---|
| Revenue | $959.00M | $814.50M | $805.50M | $794.90M | $687.50M |
| Gross profit | $935.80M | $800.70M | $787.90M | $780.90M | $677.20M |
| Operating income | $153.00M | $186.00M | $227.90M | $239.30M | $145.60M |
| Net income | $144.40M | $197.90M | $153.70M | $209.50M | $107.50M |
| Basic EPS | 1.43 | 1.97 | 1.54 | 2.11 | 1.09 |
| Diluted EPS | 1.39 | 1.91 | 1.48 | 2.04 | 1.06 |
Estimates vs actuals
Next earnings
2026-10-28
EPS estimate
2.72
Revenue estimate
$1.04B
Last surprise
+45.44%
| Date | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-10-28 | 2.72 | Not reported | — |
| 2026-07-30 | 1.96 | 2.85 | +45.44% |
| 2026-05-05 | 1.70 | 1.94 | +14.36% |
| 2026-02-11 | 2.30 | 1.88 | -18.13% |
| 2025-10-28 | 2.07 | 2.17 | +4.89% |
| 2025-07-30 | 1.50 | 1.65 | +9.64% |
| 2025-05-05 | 1.09 | 0.70 | -36.02% |
| 2025-02-06 | 1.93 | 1.69 | -12.41% |
| 2024-10-30 | 1.82 | 1.81 | -0.39% |
| 2024-08-01 | 1.53 | 1.63 | +6.76% |
| 2024-05-01 | 1.29 | 1.20 | -6.81% |
| 2024-02-07 | 1.51 | 1.54 | +1.69% |
Institutional holders
| Institution | Quarter | Value held | Portfolio weight |
|---|---|---|---|
| BlackRock Inc. | 2024-06-30 | $2B | 0.04% |
| VANGUARD GROUP INC | 2025-12-31 | $1.4B | 0.02% |
| STATE STREET CORP | 2026-06-30 | $739.1M | 0.02% |
| RENAISSANCE TECHNOLOGIES LLC | 2026-06-30 | $393.7M | 0.54% |
| TWO SIGMA INVESTMENTS, LP | 2026-06-30 | $349.9M | 0.25% |
| Bridgewater Associates, LP | 2026-06-30 | $34.7M | 0.14% |
| CITADEL ADVISORS LLC | 2026-06-30 | $2M | 0.00% |
13F quarterly filings. Reporting periods differ by institution; value and weight reflect each institution's own latest quarter.
Analyst ratings
Mean target
$211.72
Target range
$165.00 – $253.00
Implied upside
35.22%
Strong buy
4
Buy
19
Hold
4
Sell
0
Strong sell
0
Advertisement